DE60044503D1 - Die zellvermehrung hemmendes protein, polynukleotid, antisens-polynukleotid und zellvermehrungshemmer, krebsdiagnostik, krebsheilmittel und zusammensetzungen zur gentherapie - Google Patents

Die zellvermehrung hemmendes protein, polynukleotid, antisens-polynukleotid und zellvermehrungshemmer, krebsdiagnostik, krebsheilmittel und zusammensetzungen zur gentherapie

Info

Publication number
DE60044503D1
DE60044503D1 DE60044503T DE60044503T DE60044503D1 DE 60044503 D1 DE60044503 D1 DE 60044503D1 DE 60044503 T DE60044503 T DE 60044503T DE 60044503 T DE60044503 T DE 60044503T DE 60044503 D1 DE60044503 D1 DE 60044503D1
Authority
DE
Germany
Prior art keywords
polynucleotide
cancer
cell
antisens
gender
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60044503T
Other languages
English (en)
Inventor
Masayoshi Namba
Toshiya Tsuji
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60044503D1 publication Critical patent/DE60044503D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60044503T 1999-11-19 2000-08-30 Die zellvermehrung hemmendes protein, polynukleotid, antisens-polynukleotid und zellvermehrungshemmer, krebsdiagnostik, krebsheilmittel und zusammensetzungen zur gentherapie Expired - Lifetime DE60044503D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33060499 1999-11-19
PCT/JP2000/005879 WO2001038528A1 (fr) 1999-11-19 2000-08-30 Proteine inhibitrice de la proliferation cellulaire, polynucleotide, polynucleotide antisens de ce polynucleotide, inhibiteurs de proliferation cellulaire, diagnostics de cancers, remedes anticancereux et composition pour therapie genique les utilisant

Publications (1)

Publication Number Publication Date
DE60044503D1 true DE60044503D1 (de) 2010-07-15

Family

ID=18234524

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60044503T Expired - Lifetime DE60044503D1 (de) 1999-11-19 2000-08-30 Die zellvermehrung hemmendes protein, polynukleotid, antisens-polynukleotid und zellvermehrungshemmer, krebsdiagnostik, krebsheilmittel und zusammensetzungen zur gentherapie

Country Status (7)

Country Link
US (2) US20060275263A1 (de)
EP (1) EP1234877B1 (de)
JP (3) JP3813872B2 (de)
CN (1) CN1402784A (de)
AU (1) AU6865600A (de)
DE (1) DE60044503D1 (de)
WO (1) WO2001038528A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
ES2414460T3 (es) 2004-08-04 2013-07-19 Amgen Inc. Anticuerpos para Dkk-1
CN101541960B (zh) 2006-10-24 2014-03-12 公文裕巳 REIC/Dkk-3基因的部分片段和包含所述部分片段的癌症治疗剂
CN102159709B (zh) * 2008-07-30 2013-07-24 国立大学法人冈山大学 用于恶性间皮瘤的新型治疗剂和免疫刺激剂
TWI545196B (zh) 2011-05-25 2016-08-11 國立大學法人岡山大學 Ｒｅｉｃ表現腺病毒載體
WO2017057308A1 (ja) 2015-09-28 2017-04-06 国立大学法人岡山大学 活性構造のＲＥＩＣ／Ｄｋｋ－３タンパク質を特異的に認識して結合する抗体、及び該抗ＲＥＩＣ／Ｄｋｋ－３抗体を用いた癌治療のモニタリング
RU2767997C2 (ru) 2016-01-08 2022-03-22 Момотаро-Джин Инк. КОМБИНИРОВАННАЯ ТЕРАПИЯ С ИСПОЛЬЗОВАНИЕМ ГЕНА REIC/Dkk-3 И ИНГИБИТОРА КОНТРОЛЬНОЙ ТОЧКИ ИММУННОГО ОТВЕТА
US20190330291A1 (en) * 2016-06-17 2019-10-31 Momataro-Gene Inc. TGFß INHIBITOR CONTAINING REIC/Dkk-3 PROTEIN AS ACTIVE INGREDIENT
US11951182B2 (en) 2018-11-01 2024-04-09 Momotaro-Gene Inc. Combination therapy for treatment of thoracic cancer using Ad-REIC/Dkk-3 and a checkpoint inhibitor
JP7517706B2 (ja) 2019-07-31 2024-07-17 桃太郎源株式会社 ＲＥＩＣ／Ｄｋｋ－３遺伝子と抗腫瘍剤との併用による肝臓がんの治療方法
CN116133670A (zh) 2020-07-31 2023-05-16 桃太郎源株式会社 包含REIC/Dkk-3基因的EGFR基因突变阳性肺癌的治疗药

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2275540A1 (en) * 1996-12-20 1998-07-02 Human Genome Sciences, Inc. Cerebellum and embryo specific protein
EP1852507B1 (de) * 1997-04-16 2011-04-13 Millennium Pharmaceuticals, Inc. Zusammensetzung, umfassend einen Antikörper, der selektiv an ein cysteinreiches sekretiertes Protein (CRSP) bindet
NZ503343A (en) * 1997-09-17 2002-09-27 Genentech Inc Secreted and transmembrane polypeptides and use to induce apoptosis of tumour cells
US6344541B1 (en) * 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides

Also Published As

Publication number Publication date
JP2006158399A (ja) 2006-06-22
US20100204308A1 (en) 2010-08-12
US20060275263A1 (en) 2006-12-07
EP1234877A4 (de) 2002-11-06
CN1402784A (zh) 2003-03-12
JP4509018B2 (ja) 2010-07-21
JP2010163440A (ja) 2010-07-29
JP3813872B2 (ja) 2006-08-23
US9243048B2 (en) 2016-01-26
EP1234877B1 (de) 2010-06-02
AU6865600A (en) 2001-06-04
WO2001038528A1 (fr) 2001-05-31
EP1234877A1 (de) 2002-08-28

Similar Documents

Publication Publication Date Title
EP1680177A4 (de) Chirurgisches zugangssystem und relevante verfahren
ATE279190T1 (de) Synergistische zusammensetzungen zur krebsbehandlung
DE60138611D1 (de) Synergistische kombinationstherapie zur krebsbehandlung
MXPA02000992A (es) Microarreglos y su fabricacion.
EP1692085A4 (de) Inhibierung von fgfr3 und behandlung von multiplem myelom
HK1090019A1 (en) Sewage treatment system
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
DE60044503D1 (de) Die zellvermehrung hemmendes protein, polynukleotid, antisens-polynukleotid und zellvermehrungshemmer, krebsdiagnostik, krebsheilmittel und zusammensetzungen zur gentherapie
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
HK1048337A1 (en) Oligonucleotides for inhibiting the expression of human eg5.
EP1684758A4 (de) Verfahren und zusammensetzungen mit thalidomid zur behandlung und versorgung von krebs und anderen krankheiten
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
EP1694364A4 (de) System zur behandlung und prävention von brustkrebs
MXPA01011923A (es) Composiciones y metodos para tratar alteraciones en la proliferacion celular.
NO20006047L (no) Fremgangsmåte for genterapi
AU2074101A (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
HUP0104568A3 (en) Human prostatic cell lines for cancer treatment
AU2003284287A8 (en) Physician access system
ZA200108256B (en) Compositions and methods for the treatment and diagnosis of breast cancer.
ZA200203166B (en) Treatment of cancer.
AU2003269378A1 (en) Methods and compositions for diagnosing and treating companion animal cancer
GB2419530B (en) Human prostate cell lines in cancer treatment
EP1599214A4 (de) Verfahren und zusammensetzungen zur behandlung von gebärmutterhalskrebs
AU5689800A (en) Diagnosis, prognosis and treatment of cancer related to the barx2 gene
DE60017250D1 (de) Synergistische zusammensetzung zur krebsbehandlung